Literature DB >> 2713168

Long-term observation of baboons, rhesus monkeys, and chimpanzees inoculated with HIV and given periodic immunosuppressive treatment.

W J Morrow1, J Homsy, J W Eichberg, J Krowka, L Z Pan, I Gaston, H Legg, N Lerche, J Thomas, J A Levy.   

Abstract

Baboons, rhesus monkeys, and chimpanzees were injected with the human immunodeficiency virus (HIV) and monitored for up to 4 years. Various immunosuppressive regimens were used during this time in attempts to induce development of the acquired immune deficiency syndrome (AIDS). No infectious virus was recovered or anti-HIV antibodies detected in the baboons and rhesus monkeys. Virus has been recovered from lymphocyte cultures of all five of the chimpanzees at intermittent periods following inoculation. The chimpanzees developed anti-HIV antibodies from 1 to 5 months after virus inoculation and had circulating antibodies that neutralized HIV. All the infected animals were capable of in vitro lymphocyte blastogenic responses to recombinant envelope and core HIV antigens. Despite immunosuppressive therapies and evidence of some immunologic abnormalities, none of the five chimpanzees has yet developed AIDS or a related disorder.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2713168     DOI: 10.1089/aid.1989.5.233

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  9 in total

1.  A University of California State-supported AIDS research award program--a unique state and university partnership in AIDS research.

Authors:  N K Das; C L Hopper; M Jencks; J Silva
Journal:  J Clin Immunol       Date:  1991-03       Impact factor: 8.317

2.  Synthetic peptides define the fine specificity of the human immunodeficiency virus (HIV) gp160 humoral immune response in HIV type 1-infected chimpanzees.

Authors:  R Q Warren; H Wolf; K R Shuler; J W Eichberg; R A Zajac; R N Boswell; P Kanda; R C Kennedy
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

3.  Establishment of persistent HIV-1 infection in vitro is accompanied by reduction of NF-kappa B activity.

Authors:  X Zhang; P Li; C J Burrell
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

4.  Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection.

Authors:  B Chackerian; E M Long; P A Luciw; J Overbaugh
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

5.  Extensive diversification of human immunodeficiency virus type 1 subtype B strains during dual infection of a chimpanzee that progressed to AIDS.

Authors:  Q Wei; P N Fultz
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

6.  A dominant block to HIV-1 replication at reverse transcription in simian cells.

Authors:  Carsten Münk; Stephanie M Brandt; Ginger Lucero; Nathaniel R Landau
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-04       Impact factor: 11.205

7.  Isolation and characterization of a syncytium-inducing, macrophage/T-cell line-tropic human immunodeficiency virus type 1 isolate that readily infects chimpanzee cells in vitro and in vivo.

Authors:  R Shibata; M D Hoggan; C Broscius; G Englund; T S Theodore; A Buckler-White; L O Arthur; Z Israel; A Schultz; H C Lane
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

8.  Molecular cloning and characterization of viruses isolated from chimpanzees with pathogenic human immunodeficiency virus type 1 infections.

Authors:  D M Mwaengo; F J Novembre
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

9.  Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1.

Authors:  M Girard; B Meignier; F Barré-Sinoussi; M P Kieny; T Matthews; E Muchmore; P L Nara; Q Wei; L Rimsky; K Weinhold
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.